MPTP mouse studies
Toxin-induced mouse studies for protocol-defined Parkinsonian pharmacology and phenotyping.
NEUROSCIENCE MODEL
Parkinson's Disease Models
Documented Parkinson's disease platforms include MPTP-induced mouse models, B6-hSNCA E46K/A53T mice, and 6-OHDA-induced rat models.
Model mechanism, species, treatment window, behavioral assessment, tissue collection, and biomarker package are matched to the development question.
MODEL OVERVIEW
Multiple Parkinson's disease model formats for mechanism-matched pharmacology.
The reviewed partner portfolio spans toxin-induced and transgenic Parkinson's disease models, allowing study design to be aligned with the candidate mechanism and required functional or tissue-level outputs.
Therapeutic areaParkinson's disease
SpeciesMouse, Rat
Model formatMPTP, hSNCA, 6-OHDA
Typical useEfficacy, Phenotyping
TYPICAL APPLICATIONS
What this model can support.
hSNCA transgenic studies
B6-hSNCA E46K/A53T mice for programs requiring a transgenic alpha-synuclein disease context.
6-OHDA rat studies
Rat 6-OHDA models for study designs requiring a lesion-based Parkinson's disease context.
Integrated readouts
Combine protocol-defined behavioral, biomarker, exposure, and tissue outputs when required.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Behavior
Protocol-defined functional and behavioral assessments appropriate to the selected model.
Biomarkers
Mechanism-linked neurochemical or molecular biomarkers when included in the program.
Tissue analysis
Brain-region or other protocol-defined tissue collection for downstream analysis.
Exposure
Plasma, CSF, brain, or other selected exposure measurements when incorporated.
Exact strain, induction or lesion protocol, assessment schedule, tissue outputs, and study timeline are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- MPTP, hSNCA, or 6-OHDA model context
- Mouse or rat platform
- Candidate mechanism
- Treatment timing and duration
- Behavioral and tissue readouts
- PK/PD or biomarker integration
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a Parkinson's study.Required fields are marked with an asterisk(*).